An intestinal *Candida albicans* model for monomicrobial and polymicrobial biofilms and effects of hydrolases and the Bgl2 ligand

Masfufatun Masfufatun¹, Rini Purbowati¹, Nira A. Arum¹, Mey S. Yasinta², Sri Sumarsih³ and Afaf Baktir⁴

1. Department of Biochemistry, Faculty of Medicine, University of Wijaya Kusuma Surabaya, Surabaya, Indonesia; 2. Department of Biomedicine and Biomolecular, Faculty of Medicine, University of Wijaya Kusuma Surabaya, Surabaya, Indonesia; 3. Department of Chemistry, Faculty of Science and Technology, Airlangga University, Surabaya, Indonesia; 4. Department of Chemistry, Faculty of Science and Technology, Airlangga University, Surabaya, Indonesia.

**Corresponding author:** Masfufatun Masfufatun, e-mail: masfufatun@uwks.ac.id

**Co-authors:** RP: rini.purbowati@uwks.ac.id, NAA: nira.ambar.arum-2016@fst.unair.ac.id, SS: mei.irli.yasinta-2016@fst.uniar.ac.id, AB: afaf-b@fst.unair.ac.id

Received: 16-11-2021, Accepted: 14-03-2022, Published online: 29-04-2022

**doi:** www.doi.org/10.14202/vetworld.2022.1134-1140

**How to cite this article:** Masfufatun M, Purbowati R, Arum NA, Yasinta MS, Sumarsih S, Baktir A (2022) An intestinal *Candida albicans* model for monomicrobial and polymicrobial biofilms and effects of hydrolases and the Bgl2 ligand, *Veterinary World*, 15(4): 1134-1140.

**Abstract**

**Background and Aim:** *Candida albicans* is the most prevalent human fungal pathogen. In biofilms, *C. albicans* becomes more resistant to antifungal agents because of the production of an extracellular matrix (ECM) that protects the yeast cells. This study aimed to determine the effects of hydrolysis enzymes and the Bgl2 ligand on monomicrobial and polymicrobial biofilms.

**Materials and Methods:** Biofilm induction in rats was carried out using streptomycin (25 mg/kg) and gentamicin (7.5 mg/kg) administered orally once per day for 5 days. Rats were injected subcutaneously with cortisone acetate (225 mg/kg) as an immunosuppressant on day 5. In addition, rats were orally administered *C. albicans* for the single microbial model and a combination of *C. albicans* with *Escherichia coli* for the polymicrobial model. Following the biofilm production, the groups were treated with glucosamine (8.57 mg/kg body weight) and *Achatina fulica* hydrolases (1.5 mL orally for 2 weeks). The reduction of the biofilm was measured using confocal laser scanning microscopy (CLSM). Data were analyzed using a t-test, with a significance value of 95%.

**Results:** CLSM images revealed a strong association between *C. albicans* and *E. coli* in the polymicrobial biofilm. On the contrary, the combination treatment using glucosamine and *A. fulica* hydrolases reduced the ECM of the single microbial biofilm (53.58%). However, treatment effectiveness against the matrix (19.17%) was reduced in the polymicrobial model.

**Conclusion:** There is a strong association between *C. albicans* and *E. coli* in the formation of polymicrobial biofilms. The combination of glucosamine and the *A. fulica* enzyme can reduce the single microbial biofilm ECM; however, it is ineffective in the polymicrobial model.

**Keywords:** *Achatina fulica* hydrolases, Bgl2 ligand, *Candida albicans*, *Escherichia coli*, intestinal polymicrobial biofilm.

**Introduction**

The human body is a host for one billion microorganisms. *Candida albicans* is usually found in the normal human micro-ecosystem. *Candida* inhabits several body parts of humans, such as the oral cavity, gastrointestinal tract, skin, and vagina [1,2]. The virulence of *C. albicans* is related most commonly to the formation of biofilms. A biofilm is a structured microbial community covered in an extracellular matrix (ECM) and attached to a surface. The biofilm shows phenotypic characteristics different from planktonic or motile cells [3]. In the biofilm form, there is significantly greater resistance to antimicrobial agents [4-8]. The ECM is secreted by the sessile communities and protects them. It consists mainly of polysaccharides, such as glucans, mannan, and chitin, and it acts as a barrier and hampers the ability of antifungal molecules to reach the cells. However, it is not the only cause of biofilm resistance [5,9,10].

As the presence of the ECM can inhibit antifungal action, it is essential to develop research to find herbal remedies that can destroy the matrix material. Enzymatic treatment may be a good strategy to improve antifungal performance. In our previous work, we successfully inhibited biofilm formation using the Bgl2p ligand, glucosamine, as an inhibitory molecule. Bgl2p is a glucosyltransferase encoded by the Bgl2 gene. This glucosyltransferase is responsible for forming covalent bonds between 1,3-glucan and other cell wall components and ECM components [11]. In this work, we combined the action of the glucosamine ligand and the hydrolase mixture produced by *Achatina fulica* to support antimicrobial performance for hydrolysis of the ECM in the monomicrobial and polymicrobial models of *C. albicans*.

Therefore, the purposes of this study were (1) to prove the ability of *C. albicans* to form a mixed or polymicrobial intestinal biofilm with *Escherichia coli*;
(2) to evaluate the interactions between C. albicans and E. coli in biofilms from rat models; and (3) to investigate the performance of glucosamine (as the Bgl2 ligand) and the combination of A. fulica hydro-

Mater...
Shapiro–Wilk test (for samples <50). Statistical analyses were performed using the Statistical Package for the Social Sciences 16.0 software (IBM Corp., NY, USA). A value of $p<0.05$ was considered to indicate a significant difference between the control and treatment groups. All values are expressed as the mean±standard deviation.

**Results**

**Macroscopic and microscopic observations of monomicrobial and polymicrobial C. albicans biofilms in an in vivo rat model**

The *in vivo* monomicrobial *C. albicans* biofilms in the rats of Group 2 appeared as white lesions in the mucous membrane of the cecum under macroscopic evaluation (Figure-1a). The normal rat model (Group 1) showed a normal mucous membrane of the cecum without white lesions (Figure-1b). Microscopic images of *C. albicans* and the matrix of the monomicrobial biofilm model of the biofilm control group (Group 1) (c) and control group (Group 2) (d) are shown. The green and red intensities in the biofilm group (Figure-1c) were stronger than those in the control group (Figure-1d). Green fluorescence indicates the presence of *C. albicans* biofilm matrix, and red luminescence indicates the presence of *C. albicans* cells. Yellow fluorescence indicates the presence of *C. albicans* cells in the biofilm covered with the resulting ECM.

The *in vivo* polymicrobial biofilm model of Group 4 appeared as white lesions located in the mucous membrane of the cecum, as presented in Figure-2b. The normal rat model showed a normal outer mucous membrane of the cecum without white lesions, as presented in Figure-2a. There was a considerable difference in the cecum size between the normal group and the Group 4 models. Yellow fluorescence in the biofilm group (Figure-2d) is the result of overlapping red (*E. coli*) and green (*C. albicans*) images, showing that *C. albicans* cells interacted with bacterial cells to form polymicrobial biofilms. In the control group (Figure-2c), a portion was red with moderate intensity, proving that there were still many bacteria in the digestive tract.

**CLSM analysis of monomicrobial and polymicrobial C. albicans biofilms in an in vivo rat model before and after treatment**

Confocal imaging was used to assess the association between *C. albicans* and *E. coli* from the same polymicrobial model sample with different fluorescences. The confocal images of *C. albicans* and *E. coli* showed an association between these two species, as *C. albicans* mainly appeared in the same location as *E. coli*, as seen from the yellow–orange superimposed image (Figure-3a). The treatment resulted in a

**Figure-1:** Macroscopic and microscopic image of monomicrobial *Candida albicans* biofilm in cecum mucous membrane. Macroscopic: (a) Biofilm of the Group 2 rat model and (b) Normal rat model (Group 1). Biofilm shown in the red circle, appeared as white lesions. Microscopic: (c) Biofilm of the Group 2 rat model and (d) Normal rat model (Group 1). The green colored image displayed a matrix, colored using Concavaline A. The red colored image displayed *C. albicans* cells, colored using polyclonal-antibody anti- *Candida* conjugated to Tetramethyl Rhodamine Isothiocyanate. Yellow-orange colored displayed the superimposed image of *C. albicans* and matrix confocal image.

**Figure-2:** Macroscopic and microscopic image of polymicrobial *Candida albicans* biofilm in cecum mucous membrane. Macroscopic: (a) Normal rat model (Group 1) and (b) Polymicrobial biofilm of the Group 4 rat model. Biofilm shown in the red circle, appeared as white lesions. Microscopic: (c) Normal rat model (Group 1) and (d) polymicrobial biofilm of the Group 4 rat model. The green colored image displayed *C. albicans* cells, colored using polyclonal-antibody anti- *Candida*-fluorescein isothiocyanate. The red colored image displayed *Escherichia coli* cells, colored using SYTO-59. Yellow-orange colored displayed the superimposed image of *C. albicans* and *E. coli* confocal image.
decrease in fluorescence intensity, as evidenced by the dimmer appearance in the confocal image of the treatment group or Group 2 (Figure-3b) and the quantitative data of the mean intensity that showed a decrease in the treatment group (Figure-4). The decreased intensity was proportional to the decreased number of cells, as the fluorescence appeared due to the specific binding of the dye with parts of the cells.

The effect of *C. albicans* cells and matrix treatment in the polymicrobial model was also observed with confocal imaging. The treatment decreased *C. albicans* cells and matrix, demonstrated by the lower intensities of the confocal image fluorescence (Figure-5b), than that of the non-treatment group (Figure-5a). The decrease in intensity was proportional to the decrease in the ECM (Figure-4).

For the monomicrobial model, the results agreed with the polymicrobial biofilm model. A dimmer confocal image (Figure-6) demonstrated that the *C. albicans* cells and matrix had reduced intensities in the treatment group. Quantitatively, the monomicrobial biofilm had a smaller number of cells and matrix (indicated by the lower intensities) than the polymicrobial biofilm of the treatment group (Figure-7).

### Discussion

The biofilm lifestyle protects cells that reside within the thick layer of the ECM. The biofilm allows cells to develop up to 1000 times more resistance to antimicrobials than planktonic cells, leaving biofilm eradication a challenging task [14,15]. For *C. albicans*, the biofilms grown on surfaces show significantly increased minimum inhibitory concentrations to antifungals, including fluconazole, compared to planktonic cells [15,16].

The biofilm of *C. albicans* consists of blastospore-type cells as the basal layer and a superficial layer of ECM and hyphal-type cells. The ECM comprises carbohydrates (glucose, N-acetylglucosamine, mannose, and rhamnose), proteins, phosphorus, uronic acid, and hexosamine [9,17]. One of the carbohydrate components is β-1,3-glucan, a glucose polymer, thought to be the main ECM component in biofilms. β-1,3-Glucans are synthesized by glucan synthase, a membrane-bound protein, using uridine diphosphate glucose as a substrate and secret the molecules to the ECM. This component in *C. albicans* biofilm cells may contribute to resistance to antifungal drugs. Some studies have reported that β-1,3-glucans can be found in the supernatant around the biofilm and in the matrix. The level of this substance increased to a high concentration during the biofilm formation phase. The other evidence is that enzymatic treatment of β-1,3-glucans using β-1,3-glucanase at high concentrations eliminates biofilms but does not significantly affect planktonic cells. Enzymatic treatment using β-1,3-glucanase at low concentrations poorly disrupts biofilms; however, in combination with fluconazole, it improves the performance of the antifungal [18-20]. A previous study by Nett et al. [20] also suggested that β-1,3-glucans bind to fluconazole in biofilms, decreasing the antifungal efficacy to control biofilm-associated cells. Therefore, disrupting the β-1,3-glucan component using β-1,3-glucanase is a good strategy to support antifungal effectiveness.

The roles of several genes in the biofilm formation process have been investigated. The glucan transferases Phr1p and Bgl2p, encoded by *PHR1* and *BGL2*, respectively, and exoglucanase, encoded by...
XOG1, are predicted to exist in the ECM and have the roles of delivering and accumulating \(\beta\)-1,3-glucans in the ECM. Mutant strains lacking these genes show more susceptibility to fluconazole [21]. Therefore, the competitive inhibition of enzymes responsible for biofilm construction, such as Bgl2p, can be an effective way to promote the antimicrobial potential for killing cells directly.

A. fulica is a natural source of several hydrolase enzymes. It produces the enzyme mixture through the digestive gland to help digest food. However, several nondigestible materials are digested by the microbial enzymes produced in their gastrointestinal tract. The enzyme mixtures of the digestive tract of this species are carbohydrases, such as mannosidase, glucosidase, chitinase, \(\beta\)-glucanases, proteinase, and lipase [22-25].

The utilization of A. fulica might reduce the cost of enzyme production, as this species is fairly abundant, especially in a tropical and humid area like Indonesia. The enzymes from A. fulica can successfully lyse the fungal cell wall of Candida spp. [26]. Candida spp. cell walls have components similar to the ECM, with \(\beta\)-1,3-glucans and \(\beta\)-1,6-glucan being the major carbohydrate components (50%–60%). Therefore, the enzyme mixtures of A. fulica have great potential as an affordable and effective antibiofilm treatment, as supported by Nett et al. [20], wherein treatment with \(\beta\)-1,3-glucanase was highly effective in eradicating C. albicans biofilms.

Therefore, we hypothesized that the combination of treatment using A. fulica mixture hydrolases and the Bgl2 ligand, the glucose substrate look-alike, glucosamine (Figure-8), could work synergistically to enhance the eradication of the ECM and increase the killing of pathogenic cells that reside within the ECM. The matrix was decreased through hydrolysis of its complex polymer components, mainly \(\beta\)-1,3-glucan, to oligomers or monomers. The ligand, glucosamine, binds to the specific binding site of glucan transferase, replacing its original substrate, glucose, and inhibits \(\beta\)-1,3-glucan delivery and the accumulation of \(\beta\)-1,3-glucan in the matrix, thus further disrupting biofilm formation. However, in this study, we did not compare the performance of this potential antibiofilm as a combination and as separate components. We compared the action of this combined treatment with the results of the in vivo application of the monomicrobial and polymicrobial biofilm model.

Biofilms consisting of single microbial species have been extensively studied; however, more recent investigations have found that polymicrobial biofilms...
are the dominant form in nature. This study investigated the interaction between bacteria and fungi in a polymicrobial biofilm model composed of *E. coli* and *C. albicans*. Both species are predominant pathogens that can grow as biofilms in medical devices [2]. This study demonstrated that ECM disruption using a ligand–enzyme combination treatment in the monomicrobial biofilm model was more effective than the treatment in the polymicrobial biofilm model. The ECM was decreased significantly by 53.58% in the monomicrobial model. However, in the polymicrobial model, the treatment decreased the matrix intensity by 19.17%; this decrease was also significant (Figures-4 and 7). The difference in the ligand–enzyme performance against the matrix material might be because of the strong and synergistic association between *E. coli* and *C. albicans*. A previous study stated that *E. coli* might facilitate the attachment of *C. albicans* to the host surface, resulting in stronger binding between the cells and the host [27,28].

**Conclusion**

Treatment targeting matrix hydrolysis and the inhibition of Bgl2 using a combination of antimicrobials successfully reduced the biofilm matrix of *E. coli* and *C. albicans*. In this study, we have found a mixture of glucosamine and Bgl2 enzyme as herbal remedies to destroy the matrix material of *C. albicans* biofilm in the monomicrobial model. However, it showed limited activity towards polymicrobial biofilm of *C. albicans* and *E. coli*. In the next study we will explore antibiofilm especially for *E.coli*.

**Authors’ Contributions**

MM: Conceived and designed the study, performed the experimental work, and reviewed the manuscript. NAA and MSY: Collected microorganisms isolates and reviewed the manuscript. AB and RP: Data interpretation, statistical study, and reviewed the manuscript. SS: Conducted the literature review and drafted the manuscript. All authors have read and approved the final manuscript.
Acknowledgments

The authors would like to thank Directorate of Research and Community Service, Directorate General Strengthening for Research and Development of the Ministry of Research, Technology and Higher Education of the Republic of Indonesia for the research funding.

Competing Interests

The authors declare that they have no competing interests.

Publisher’s Note

Veterinary World remains neutral with regard to jurisdictional claims in published institutional affiliation.

References

1. Harriott, M.M. and Noverr, M.C. (2011) Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol., 19(11): 557-563.
2. Samaranayake, Y.H., Bandara, H.M.H., Cheung, B.P.K., Yau, J.Y.Y., Yeung, S.K.W. and Samaranayake, L.P. (2014) Enteric Gram-negative bacilli suppress Candida biofilms on Foley urinary catheters. APMSIS, 122(1): 47-58.
3. Gulati, M. and Nobile, C.J. (2016) Candida albicans biofilms: Development, regulation, and molecular mechanisms. Microbes Infect., 18(5): 310-321.
4. Mayer, F.L., Wilson, D. and Hube, B. (2013) Candida albicans pathogenicity mechanisms. Virulence, 4(2): 119-128.
5. Nobile, C.J. and Johnson, A.D. (2015) Candida albicans biofilms and human disease. Annu. Rev. Microbiol., 69: 71-92.
6. Fu, J., Ding, Y., Wei, B., Wang, L., Xu, S., Qin, P., Wei, L. and Jiang, L. (2017) Epidemiology of Candida albicans and non-C. albicans of neonatal candidemia at a tertiary care hospital in Western China. BMC Infect. Dis., 17(1): 329.
7. Bitew, A. and Abebaw, Y. (2018) Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health, 18(1): 94.
8. Ou, H.T., Lee, T.Y., Chen, Y.C. and Charbonneau, C. (2017) Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. BMC Infect. Dis., 17: 481.
9. Pierres, C.G., Vila, T., Romo, J.A., Montelongo-Jauregui, D., Wall, G., Ramasubramanian, A. and Lopez-Ribot, J.L. (2017) The Candida albicans biofilm matrix: Composition, structure and function. J. Fungi., 3(1): 14.
10. Zarnowski, R., Westler, W.M., de Lacambouh, G.A., Marita, J.M., Bothe, J.R., Bernhardt, J., Sahraoui, A.L.H., Fontaine, J., Sanchez, H., Hatfield, R.D., Nambi, J.M., Nett, J.E., Mitchell, A.P. and Andes, D.R. (2014) Novel entries in a fungal biofilm matrix encyclopedia. mBio, 5(4): e01333-e10134.
11. Hartland, R.P., Emerson, G.W. and Sullivan, P.A. (1991) A secreted formula-glucan-branching enzyme from Candida albicans. Proc. R. Soc. B Biol. Sci., 246(1316): 155-160.
12. Masufutun, M., Raharjo, L.H., Wiradinata, H., Tania, P.O.A., Ni’matuzahroh, N. and Baktir, A. (2021) New phenomena for clinicians, model of Candida albicans mobilization before and after biofilm formation in the intestinal mucosa of Wistar rats (Rattus norvegicus). Int. J. One Health, 7(2): 165-170.
13. Baktir, A., Masufutun and Hadi, S. (2015) Preclinical study of Bgl2 ligand as component of mix antibiofilm to Candida albicans on mucous intestinal biofilm pre-induced Rattus norvegicus. Pharm. Chem., 7(3): 113-118.
14. Sherry, L., Rajendran, R., Lappin, D.F., Borghi, E., Perdoni, F., Falleni, M., Tosi, D., Smith, K., Williams, C., Jones, B., N. C.J. and Ramage, G. (2014) Biofilms formed by Candida albicans bloodstream isolates display phenotype and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol., 14: 182.
15. Lara, H.H., Urbina, D.G.R., Pierce, C., Ribot, J.L.L., Jiménez, M.J.A. and Yacaman, M.J. (2015) Effect of silver nanoparticles on Candida albicans biofilms: An ultrastructural study. J. Nanobiotechnol., 13: 91.
16. Chandra, J. and Mukherjee, P.K. (2015) Candida biofilms: Development, architecture, and resistance. Microbiol. Spectrom., 3(4): 1-24.
17. Lal, P., Sharma, D., Pruthi, P. and Pruthi, V. (2010) Exopolysaccharide analysis of biofilm-forming Candida albicans. J. Appl. Microbiol., 109(1): 128-136.
18. Al-Fattani, M.A. and Douglas, L.J. (2006) Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition and role in drug resistance. J. Med. Microbiol., 55(Pt 8): 999-1008.
19. Nett, J.E., Cain, M.T., Crawford, K., Andes, D.R., Middleton, W.S. and Hospital, V. (2011) Optimizing a Candida albicans microtiter plate model for measurement of antifungal susceptibility by tetracyclol salt assay. J. Clin. Microbiol., 49(4): 1426-1433.
20. Nett, J., Lincoln, L., Marchillo, K., Masrey, R., Holodyka, K., Hoff, B., VanHandel, M. and Andes, D. (2007) Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother., 51(2): 510-520.
21. Taft, H.T., Nett, J.E., Zarnowski, R., Ross, K.M., Sanchez, H., Cain, M.T., Hamaker, J., Mitchell, A.P. and Andes, D.R. (2012) A Candida biofilm-induced pathway for matrix glucan delivery: Implications for drug resistance. PLoS Pathog., 8(8): e1002848.
22. Karasov, W.H. and Douglas, A.E. (2013) Comparative digestive physiology William. Physiol. Behav., 3(2): 741-783.
23. Leparoux, S. and Colas, B. (1994) Digestive juice of Achatina achatina as a potential source of transglycosylation enzymes. Int. J. Biochem., 26(2): 247-254.
24. Maeda, I., Shimohigashi, Y., Kihara, H. and Ohno, M. (1996) Purification and characterization of a cellulase from the giant snail Achatina fulica. Biosci. Biotechnol. Biochem., 60(1): 122-124.
25. Agogbua, S.I.O., Anosike, E.O. and Ugochukwu, E.N. (2021) New phenomena for biofilm resistance. J. Clin. Microbiol., 55(Pt 8): 999-1008.
26. Jiménez, M.J.A. and Yacaman, M.J. (2015) Effect of silver nanoparticles on Candida albicans biofilms: An ultrastructural study. J. Nanobiotechnol., 13: 91.
27. Ezeronye, O.U. and Okerechanguc, P.O. (2001) Optimum conditions for yeast protoplast release and regeneration in Saccharomycyes cerevisiae and Candida tropicalis using gut enzymes of the giant African snail, Achatina achatina. Lett. Appl. Microbiol., 32(3): 190-193.
28. Makrid, H.C. and MacFarlane, T.W. (1983) An investigation of the factors involved in increased adherence of C. albicans to epithelial cells mediated by E. coli. Microb. Bios, 18(135-154): 177-185.
29. De Brucker, K., Tan, Y., Vints, K., Cremer, K.D., Braem, A., Verstraeten, N., Michiels, J., Vleugels, J., Cammue, B.P.A. and Thevissen, K. (2015) Fungal beta-1,3-glucan increases ofloxacin tolerance of Escherichia coli in a polymicrobial E. coli/Candida albicans biofilm. Antimicrob. Agents Chemother., 59(6): 3052-3058.

**********